Pharmaceutical and Medicinal Chemistry , Saarland University , Campus C2.3, 66123 Saarbrücken , Germany.
Université de Lyon, Université Lyon 1, Faculté de Pharmacie, ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453, INSERM US7, F-69373 , Lyon Cedex 08, France.
J Med Chem. 2019 Feb 28;62(4):1803-1816. doi: 10.1021/acs.jmedchem.8b01766. Epub 2019 Feb 18.
CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various signaling pathways and is known to be constitutively active. In the present study, we identified aryl 2-aminothiazoles as a novel class of CK2 inhibitors, which displayed a non-ATP-competitive mode of action and stabilized an inactive conformation of CK2 in solution. Enzyme kinetics studies, STD NMR, circular dichroism spectroscopy, and native mass spectrometry experiments demonstrated that the compounds bind in an allosteric pocket outside the ATP-binding site. Our data, combined with molecular docking studies, strongly suggested that this new binding site was located at the interface between the αC helix and the flexible glycine-rich loop. A first hit optimization led to compound 7, exhibiting an IC of 3.4 μM against purified CK2α in combination with a favorable selectivity profile. Thus, we identified a novel class of CK2 inhibitors targeting an allosteric pocket, offering great potential for further optimization into anticancer drugs.
CK2 是一种普遍存在的丝氨酸/苏氨酸蛋白激酶,参与多种信号通路的调控,且已知其处于持续激活状态。在本研究中,我们鉴定出芳基 2-氨基噻唑是一种新型的 CK2 抑制剂,其表现出非 ATP 竞争性作用模式,并在溶液中稳定 CK2 的非活性构象。酶动力学研究、STD NMR、圆二色性光谱和天然质谱实验表明,这些化合物结合在 ATP 结合位点之外的别构口袋中。我们的数据与分子对接研究相结合,强烈表明这个新的结合位点位于 αC 螺旋和柔性甘氨酸丰富环之间的界面上。首次命中优化得到了化合物 7,其对纯化的 CK2α 的 IC 为 3.4 μM,同时具有良好的选择性特征。因此,我们鉴定出了一类新型的靶向别构口袋的 CK2 抑制剂,为进一步优化为抗癌药物提供了巨大的潜力。